ArticleDrug delivery2022
Prostate-specific membrane antigen targeted, glutathione-sensitive nanoparticles loaded with docetaxel and enzalutamide for the delivery to prostate cancer.
Article in Drug delivery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- Review
- Targeting the Androgen Receptor and Associated Cofactors in Prostate Cancer: Novel Approaches and Future Perspectives.International journal of molecular sciences · 2026Review
- Nanomaterial-mediated functional remodeling of antigen-presenting cells: A novel strategy to break tumor immune escape.Acta pharmaceutica Sinica. B · 2026Review
- Targeting prostate adenocarcinoma tumor microenvironment via cancer nanotheranostics: a comprehensive update on improved roadmap for disease diagnosis, therapy and management.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Global research landscape and technological breakthroughs in post-prostatectomy urinary incontinence management: a bibliometric review and visualized study.Translational andrology and urology · 2026Article
- Dysregulation of ferroptosis-related genes and the ACSL4-mediated ferroptosis-PD-L1 axis in prostate cancer pathogenesis.Cancer cell international · 2026Article
- A Hybrid Nanosystem for Prostate Cancer Therapy: Codelivery of Enzalutamide and Curcumin via Selenium-Embedded Mesoporous Silica and Chitosan Nanoparticles.ChemistryOpen · 2026Article
- Conductive Hydrogels in Biomedical Engineering: Recent Advances and a Comprehensive Review.Gels (Basel, Switzerland) · 2026Review
- Integrative Multiomics Analysis Identifies a Novel Gene Signature That Predicts Chemotherapy Resistance and Poor Survival in Osteosarcoma.Human mutation · 2026Article
- Precise delivery and controlled release: strategies and advances in TLR7/8 agonist prodrugs for cancer immunotherapy.Frontiers in immunology · 2026Review
- Survival benefit of radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched SEER database analysis.International urology and nephrology · 2025Article
- Printable Conductive Hydrogels and Elastomers for Biomedical Application.Gels (Basel, Switzerland) · 2025Review
- A comprehensive overview of triptolide utilizing nanotechnology and its potential applications in prostate diseases.Frontiers in pharmacology · 2025Review
- Laser-activated nanoparticles for ultrasound/photoacoustic imaging-guided prostate cancer treatment.Frontiers in bioengineering and biotechnology · 2023Article
- Binary Nanodrug-Delivery System Designed for Leukemia Therapy: Aptamer- and Transferrin-Codecorated Daunorubicin- and Luteolin-Coloaded Nanoparticles.Drug design, development and therapy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer (PCa) is the most common malignant tumor in men. Chemotherapy with docetaxel (DTX) and novel hormonal agents such as enzalutamide (EZL) and abiraterone are the preferred first-line therapeutic regimens. Prostate-specific membrane antigen (PSMA) is overexpressed on the surface of PCa cells. This study aimed to prepare a PSMA targeted (Glutamate-Urea-Lysine, GUL ligand modified), glutathione (GSH)-sensitive (Cystamine, SS), DTX and EZL co-loaded nanoparticles (GUL-SS DTX/EZL-NPs) to treat PCa. Polyethylene glycol (PEG) was conjugated with oleic acid (OA) using a GSH-sensitive ligand: cystamine (PEG-SS-OA). GUL was covalently coupled to PEG-SS-OA to achieve GUL-PEG-SS-OA. GUL-PEG-SS-OA was used to prepare GUL-SS DTX/EZL-NPs. To evaluate the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.